Several sources of evidence have shown that the renal kallikrein-kinin system is altered in various forms of hypertension. The impact of these results is limited by the possible dependence of urinary kallikrein excretion on the effective renal mass which might be reduced in hypertension due to nephrosclerosis and/or the underlying inflammatory kidney disease. Therefore, investigations of the kallikrein-kinin system in other kallikrein-containing tissues might be of interest. In normal subjects, the kallikrein excretion of parotid saliva is inversely related to flow rate and sodium concentration. An increased salivary kallikrein concentration is found in human essential, adrenomedullary and renoparenchymal hypertension associated with impaired kidney function. In contrast to the kallikrein secretion, the flow-dependent sodium concentration of parotid saliva is reduced in human essential and renoparenchymal hypertension which indicates an enhanced sodium reabsorption in the glandular duct system. Furthermore, in most forms of hypertension, there is a tendency of higher potassium levels in the saliva. The pathogenesis of the enhanced glandular kallikrein secretion in hypertension is discussed with regard to a counter-regulatory mechanism in hypertension as well as a sympathicoadrenergic activation. The enhanced sodium reabsorption in the duct system during various forms of hypertension could be the cause as well as the consequence of the high blood pressure.

This content is only available via PDF.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.